Compare American Airlines Group Inc (AAL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Airlines Group Inc vs GeneDx Holdings Corp — how do they compare? American Airlines Group Inc trades at $16.65 (market cap $11.38B), while GeneDx Holdings Corp trades at $64.36 (market cap $1.94B). The key difference: American Airlines Group Inc is far larger — about 5.9× GeneDx Holdings Corp's market cap, and American Airlines Group Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| AAL | WGS | |
|---|---|---|
Market Cap | $11.38B | $1.94B |
Sector | Industrials | Technology |
52-Week High | $18.15 | $167.51 |
52-Week Low | $10.18 | $34.51 |
Enterprise Value | $38.97B | $1.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.
Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.
GeneDx Holdings Corp. (WGS) trades at $68.89, up 2.04% today, with a bullish technical signal from moving averages and a consensus analyst price target of $75.40. Despite recent earnings beats in Q3 and Q4 2025, the company reported a net loss of -$21.02M in 2025, with profitability metrics like ROE at -30.42% reflecting operational challenges. The stock faces headwinds from a securities class action lawsuit alleging fraud, as noted in multiple legal alerts from July 2026.
The outlook is mixed: strong analyst buy ratings (90.91%) suggest upside potential, but negative margins and legal risks pose significant threats. Investors should weigh the high valuation multiples, such as EV/EBITDA of 161.17, against growth prospects in the genomics sector, with cash flow trends showing volatility into 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
